Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal "MIRACLE" Phase 3 AML Trial on Pace for Q1 2026
Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill
Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia "MIRACLE" Clinical Trial at the 14th Annual Acute Leukemia Meeting
Eagle Energy Metals Corp. and Spring Valley Acquisition Corp. II Announce Effectiveness of Registration Statement and Record and Meeting Dates for Extraordinary General Meeting of Shareholders to Approve Proposed Business Combination
